Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Share:
Related GHDX
2 Small Cap Pharma Stocks Credit Suisse Loves
Genomic Health Announces Favorable Draft Local Coverage Determination from Palmetto GBA on Medicare Coverage for the Oncotype DX Prostate Cancer Test
Notable earnings after Tuesday's close (Seeking Alpha)

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Latest Ratings for GHDX

DateFirmActionFromTo
May 2015JMP SecuritiesMaintainsMarket Outperform
Mar 2015UBSInitiates Coverage onNeutral
Feb 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GHDX)

Get Benzinga's Newsletters